FY2019 EPS Estimates for Uniqure NV (NASDAQ:QURE) Boosted by Cantor Fitzgerald

Uniqure NV (NASDAQ:QURE) – Analysts at Cantor Fitzgerald upped their FY2019 earnings per share (EPS) estimates for Uniqure in a research note issued to investors on Monday, July 8th. Cantor Fitzgerald analyst E. Piros now expects that the biotechnology company will post earnings of ($2.86) per share for the year, up from their previous forecast of ($2.90). Cantor Fitzgerald currently has a “Overweight” rating and a $94.00 target price on the stock.

A number of other research firms have also weighed in on QURE. BidaskClub upgraded Westport Fuel Systems from a “hold” rating to a “buy” rating in a report on Friday. Robert W. Baird started coverage on Uniqure in a report on Thursday, March 28th. They set an “outperform” rating and a $85.00 target price for the company. HC Wainwright set a $73.00 target price on Uniqure and gave the stock a “buy” rating in a report on Monday, July 8th. Zacks Investment Research lowered Farmland Partners from a “hold” rating to a “sell” rating in a report on Friday. Finally, SunTrust Banks upped their target price on Everbridge to $87.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $78.18.



Uniqure stock opened at $70.32 on Thursday. The business’s fifty day moving average is $71.87. The company has a debt-to-equity ratio of 0.38, a quick ratio of 9.51 and a current ratio of 9.51. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -30.05 and a beta of 1.05. Uniqure has a twelve month low of $21.98 and a twelve month high of $82.49.

Uniqure (NASDAQ:QURE) last posted its earnings results on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.03). The company had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $2.00 million. Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%.

Several hedge funds have recently modified their holdings of QURE. Harvest Group Wealth Management LLC acquired a new position in shares of Uniqure during the first quarter worth $26,000. Legal & General Group Plc increased its position in shares of Uniqure by 264.2% during the fourth quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 700 shares in the last quarter. Pearl River Capital LLC acquired a new position in shares of Uniqure during the first quarter worth $32,000. Financial Gravity Wealth Inc. acquired a new position in shares of Uniqure during the first quarter worth $153,000. Finally, First Citizens Bank & Trust Co. acquired a new position in shares of Uniqure during the second quarter worth $211,000. 60.10% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Philip Astley-Sparke sold 6,000 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $63.63, for a total transaction of $381,780.00. Following the transaction, the director now directly owns 18,872 shares of the company’s stock, valued at $1,200,825.36. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Christian Klemt sold 1,546 shares of the company’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total value of $88,400.28. Following the transaction, the insider now directly owns 54,539 shares in the company, valued at $3,118,540.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,546 shares of company stock worth $1,556,820. Insiders own 2.91% of the company’s stock.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Further Reading: What are the advantages of the Stochastic Momentum Index?

Earnings History and Estimates for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.